{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:42:56Z","timestamp":1768279376297,"version":"3.49.0"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine how serologic responses to coronavirus disease 2019 (COVID-19) vaccination and infection in immune-mediated inflammatory disease (IMID) are affected by time since last vaccination and other factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Post\u2013COVID-19 vaccination, data, and dried blood spots or sera were collected from adults with rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis and spondylarthritis, and psoriasis and psoriatic arthritis. The first sample was collected at enrollment, then at 2 to 4 weeks and 3, 6, and 12 months after the latest vaccine dose. Multivariate generalized estimating equation regressions (including medications, demographics, and vaccination history) evaluated serologic response, based on log-transformed anti\u2013receptor-binding domain (RBD) IgG titers; we also measured antinucleocapsid (anti-N) IgG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Positive associations for log-transformed anti-RBD titers were seen with female sex, number of doses, and self-reported COVID-19 infections in 2021 to 2023. Negative associations were seen with prednisone, anti\u2013tumor necrosis factor agents, and rituximab. Over the 2021-2023 period, most (94%) of anti-N positivity was associated with a self-reported infection in the 3 months prior to testing. From March 2021 to February 2022, anti-N positivity was present in 5% to 15% of samples and was highest in the post-Omicron era, with antinucleocapsid positivity trending to 30% to 35% or higher as of March 2023. Anti-N positivity in IMID remained lower than Canada\u2019s general population seroprevalence (&gt; 50% in 2022 and &gt; 75% in 2023). Time since last vaccination was negatively associated with log-transformed anti-RBD titers, particularly after 210 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when &gt; 6 months has elapsed since last COVID-19 vaccination\/infection.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1214","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T12:25:14Z","timestamp":1713183914000},"page":"721-727","source":"Crossref","is-referenced-by-count":7,"title":["When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-2957","authenticated-orcid":false,"given":"Dawn M.E.","family":"Bowdish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Hitchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-663X","authenticated-orcid":false,"given":"J. Antonio","family":"Avina-Zubieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-2596","authenticated-orcid":false,"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie J.","family":"Larch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claude","family":"Gingras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya M.","family":"Dayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-8334","authenticated-orcid":false,"given":"Ines","family":"Colmegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luck","family":"Lukusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-0017","authenticated-orcid":false,"given":"Jennifer L.F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn P.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania H.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Lacaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-933X","authenticated-orcid":false,"given":"Jenna","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Lalonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Gunderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Allard-Chamard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Hracs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the SUCCEED Investigative Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024070105201319000_51.7.721.1","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1001\/jama.2023.5348","article-title":"Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in fall-winter 2022-2023","volume":"329","author":"Xie","year":"2023","journal-title":"JAMA"},{"key":"2024070105201319000_51.7.721.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181376"},{"key":"2024070105201319000_51.7.721.3","doi-asserted-by":"crossref","first-page":"839433","DOI":"10.3389\/fimmu.2022.839433","article-title":"Mind the \u201cvaccine fatigue\u201d","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"2024070105201319000_51.7.721.4","unstructured":"COVID-19 Immunity Task Force . The COVID-19 Immunity Task Force [Internet. Accessed April 20, 2024.] Available from: https:\/\/www.covid19immunitytaskforce.ca\/"},{"key":"2024070105201319000_51.7.721.5","doi-asserted-by":"crossref","first-page":"e1380","DOI":"10.1002\/cti2.1380","article-title":"A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination","volume":"11","author":"Colwill","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"2024070105201319000_51.7.721.6","first-page":"e071397","article-title":"Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-center prospective cohort study","volume":"13","author":"Hitchon","year":"2023","journal-title":"BMJ"},{"key":"2024070105201319000_51.7.721.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327440"},{"key":"2024070105201319000_51.7.721.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325238"},{"key":"2024070105201319000_51.7.721.9","doi-asserted-by":"publisher","DOI":"10.1177\/1094428104263672"},{"key":"2024070105201319000_51.7.721.10","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1300"},{"key":"2024070105201319000_51.7.721.11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.2300190","article-title":"Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in adult patients with immune-mediated inflammatory diseases","volume":"211","author":"Cheung","year":"2023","journal-title":"J Immunol"},{"key":"2024070105201319000_51.7.721.12","unstructured":"Centers for Disease Control and Prevention . COVID-19 vaccines for moderately to severely immunocompromised people [Internet. Accessed April 20, 2024.] Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html"},{"key":"2024070105201319000_51.7.721.13","unstructured":"Government of Canada . COVID-19 vaccine: Canadian immunization guide [Internet. Accessed April 20, 2024.] Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-26-covid-19-vaccine.html"},{"key":"2024070105201319000_51.7.721.14","first-page":"100461","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada","volume":"20","author":"Bahremand","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2024070105201319000_51.7.721.15","doi-asserted-by":"crossref","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups","volume":"125","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"2024070105201319000_51.7.721.16","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024070105201319000_51.7.721.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106700"},{"key":"2024070105201319000_51.7.721.18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S2468-1253(22)00340-5","article-title":"Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease","volume":"7","author":"Quan","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024070105201319000_51.7.721.19","unstructured":"Government of Canada . Ottawa: Government of Canada. Vaccines for COVID-19: how to get vaccinated [Internet. Accessed April 20, 2024.] Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/coronavirus-disease-covid-19\/vaccines\/how-vaccinated.html"},{"key":"2024070105201319000_51.7.721.20","unstructured":"Centers for Disease Control and Prevention . Infection-induced and vaccine-induced immunity [Internet. Accessed April 20, 2024.] Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/vaccine-induced-immunity.html"},{"key":"2024070105201319000_51.7.721.21","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.230249"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T12:22:03Z","timestamp":1719836523000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3899\/jrheum.2023-1214"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1214","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}